Skip to main content

Table 1 Patient characteristics and outcomes

From: Plasma endostatin may improve acute kidney injury risk prediction in critically ill patients

Variable No AKI
(n = 72)
AKI
(n = 21)
P value
Age (years) 50 (28, 65) 66 (57, 71) 0.002
Female gender 22 (31 %) 5 (24 %) 0.79
APACHE II score 15 (11, 19) 19 (14, 24) 0.01
Body weight (kg) 78 (70, 90) 88 (79, 93) 0.06
Baseline creatinine (µmol/l) 82 (69, 91) 83 (71, 88) 0.69
True baseline creatinine available 52 (72 %) 12 (57 %) 0.28
Time admission–enrolled (h) 12 (5, 23) 8 (3, 14) 0.10
Time from first biomarker analysis to AKI diagnosis (days) N/A 1.0 (0.5, 1.5)  
Comorbidity    
 Diabetes 6 (8 %) 5 (24 %) 0.12
 Cardiovascular disease 20 (28 %) 11 (52 %) 0.06
 COPD/asthma 5 (7 %) 2 (10 %) 0.65
 Gastrointestinal/liver disease 2 (3 %) 3 (14 %) 0.07
 Any malignancy 11 (15 %) 3 (14 %) 1.0
Admission diagnosis    
 Neurologic 4 (6 %) 1 (5 %) 0.03
 Respiratory 14 (19 %) 6 (29 %)  
 Cardiovascular 2 (3 %) 5 (24 %)  
 Trauma 37 (51 %) 7 (33 %)  
 Gastrointestinal 3 (4 %) 1 (5 %)  
 Sepsis 12 (17 %) 1 (5 %)  
Outcome    
 ICU length of stay, days 5 (3, 9) 4 (3, 8) 0.72
 ICU mortality 4 (6 %) 2 (10 %) 0.62
 30-day mortality 8 (11 %) 4 (19 %) 0.46
  1. Values are median (interquartile range) or n (%)